IFNG and hemophagocytic syndrome: Emapalumab, a monoclonal antibody targeting interferon-gamma (IFN-γ), a key cytokine in HLH pathogenesis, has received FDA approval for pediatric and adult patients with primary HLH who have refractory or recurrent disease or who cannot tolerate conventional therapy [51].